Similar articles for PMID: 37474267

Year	Number of Results
2004	2
2006	1
2008	1
2009	1
2010	1
2011	3
2012	4
2013	6
2014	7
2015	9
2016	11
2017	13
2018	13
2019	16
2020	13
2021	33
2022	28
2023	47
2024	44
2025	2

1

Head-to-Head Comparison of ⁶⁸Ga-NODAGA-JR11 and ⁶⁸Ga-DOTATATE PET/CT in Patients with Metastatic, Well-Differentiated Neuroendocrine Tumors: Interim Analysis of a Prospective Bicenter Study.

Lin Z, Zhu W, Zhang J, Miao W, Yao S, Huo L. Lin Z, et al. J Nucl Med. 2023 Sep;64(9):1406-1411. doi: 10.2967/jnumed.122.264890. Epub 2023 Jul 20. J Nucl Med. 2023. PMID: 37474267 Free article.

2

Head-to-Head Comparison of ⁶⁸Ga-DOTA-JR11 and ⁶⁸Ga-DOTATATE PET/CT in Patients with Metastatic, Well-Differentiated Neuroendocrine Tumors: A Prospective Study.

Zhu W, Cheng Y, Wang X, Yao S, Bai C, Zhao H, Jia R, Xu J, Huo L. Zhu W, et al. J Nucl Med. 2020 Jun;61(6):897-903. doi: 10.2967/jnumed.119.235093. Epub 2019 Nov 1. J Nucl Med. 2020. PMID: 31676731 Free PMC article.

3

A prospective randomized, double-blind study to evaluate the diagnostic efficacy of ⁶⁸Ga-NODAGA-LM3 and ⁶⁸Ga-DOTA-LM3 in patients with well-differentiated neuroendocrine tumors: compared with ⁶⁸Ga-DOTATATE.

Zhu W, Jia R, Yang Q, Cheng Y, Zhao H, Bai C, Xu J, Yao S, Huo L. Zhu W, et al. Eur J Nucl Med Mol Imaging. 2022 Apr;49(5):1613-1622. doi: 10.1007/s00259-021-05512-y. Epub 2021 Dec 7. Eur J Nucl Med Mol Imaging. 2022. PMID: 34874478 Clinical Trial.

4

Gallium-68 labeled somatostatin receptor antagonist PET/CT in over 500 patients with neuroendocrine neoplasms: experience from a single center in China.

Liu M, Cheng Y, Bai C, Zhao H, Jia R, Chen J, Zhu W, Huo L. Liu M, et al. Eur J Nucl Med Mol Imaging. 2024 Jun;51(7):2002-2011. doi: 10.1007/s00259-024-06639-4. Epub 2024 Feb 10. Eur J Nucl Med Mol Imaging. 2024. PMID: 38337073

5

Evaluation of the safety, biodistribution, dosimetry of [¹⁸F]AlF-NOTA-LM3 and head-to-head comparison with [⁶⁸Ga]Ga-DOTATATE in patients with well-differentiated neuroendocrine tumors: an interim analysis of a prospective trial.

Liu M, Ren C, Zhang H, Zhang Y, Huang Z, Jia R, Cheng Y, Bai C, Xu Q, Zhu W, Huo L. Liu M, et al. Eur J Nucl Med Mol Imaging. 2024 Oct;51(12):3719-3730. doi: 10.1007/s00259-024-06790-y. Epub 2024 Jun 15. Eur J Nucl Med Mol Imaging. 2024. PMID: 38878175 Clinical Trial.

6

A Prospective, Randomized, Double-Blind Study to Evaluate the Safety, Biodistribution, and Dosimetry of ⁶⁸Ga-NODAGA-LM3 and ⁶⁸Ga-DOTA-LM3 in Patients with Well-Differentiated Neuroendocrine Tumors.

Zhu W, Cheng Y, Jia R, Zhao H, Bai C, Xu J, Yao S, Huo L. Zhu W, et al. J Nucl Med. 2021 Oct;62(10):1398-1405. doi: 10.2967/jnumed.120.253096. Epub 2021 Feb 12. J Nucl Med. 2021. PMID: 33579804 Free PMC article. Clinical Trial.

7

Sensitivity Comparison of ⁶⁸Ga-OPS202 and ⁶⁸Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase II Imaging Study.

Nicolas GP, Schreiter N, Kaul F, Uiters J, Bouterfa H, Kaufmann J, Erlanger TE, Cathomas R, Christ E, Fani M, Wild D. Nicolas GP, et al. J Nucl Med. 2018 Jun;59(6):915-921. doi: 10.2967/jnumed.117.199760. Epub 2017 Nov 30. J Nucl Med. 2018. PMID: 29191855 Free article. Clinical Trial.

8

A prospective head-to-head comparison of ⁶⁸ Ga-NOTA-3P-TATE-RGD and ⁶⁸ Ga-DOTATATE in patients with gastroenteropancreatic neuroendocrine tumours.

Jiang Y, Liu Q, Wang G, Sui H, Wang R, Wang J, Zhu Z. Jiang Y, et al. Eur J Nucl Med Mol Imaging. 2022 Oct;49(12):4218-4227. doi: 10.1007/s00259-022-05852-3. Epub 2022 Jun 3. Eur J Nucl Med Mol Imaging. 2022. PMID: 35657429 Clinical Trial.

9

Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.

Wild D, Bomanji JB, Benkert P, Maecke H, Ell PJ, Reubi JC, Caplin ME. Wild D, et al. J Nucl Med. 2013 Mar;54(3):364-72. doi: 10.2967/jnumed.112.111724. Epub 2013 Jan 7. J Nucl Med. 2013. PMID: 23297077 Free article. Clinical Trial.

10

¹⁸F-AlF-NOTA-Octreotide Outperforms ⁶⁸Ga-DOTATATE/NOC PET in Neuroendocrine Tumor Patients: Results from a Prospective, Multicenter Study.

Pauwels E, Cleeren F, Tshibangu T, Koole M, Serdons K, Boeckxstaens L, Dekervel J, Vandamme T, Lybaert W, den Broeck BV, Laenen A, Clement PM, Geboes K, Cutsem EV, Stroobants S, Verslype C, Bormans G, Deroose CM. Pauwels E, et al. J Nucl Med. 2023 Apr;64(4):632-638. doi: 10.2967/jnumed.122.264563. Epub 2022 Oct 20. J Nucl Med. 2023. PMID: 36265911 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

196 results

Results by year

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Similar articles for PMID: 37474267

196 results

Results by year